Company Description
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases.
It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease.
The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy.
The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.
In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand.
Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.
Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Robert Hariri |
Contact Details
Address: 170 Park Avenue Florham Park, New Jersey 07932 United States | |
| Phone | 908 768 2170 |
| Website | celularity.com |
Stock Details
| Ticker Symbol | CELU |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001752828 |
| CUSIP Number | 151190105 |
| ISIN Number | US1511902041 |
| Employer ID | 83-1702591 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, Chief Executive Officer and Chairman |
| John R. Haines | Senior EVice President, Corporate Secretary, Global Manager and Chief Administrative Officer |
| Joseph C. DosSantos CPA, MBA | Senior Vice President of Finance and Interim Chief Financial Officer |
| Carlos Ramirez | SVice President of Investor Relations |
| Dr. Stephen A. Brigido D.P.M. | President of Degenerative Diseases |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology and Drug Safety |
| Tim Wilk | Senior Vice President of Technical Operations |
| David Jakob Lemus CPA, M.S., MBA | Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2025 | 8-K | Current Report |
| Jun 6, 2025 | 8-K | Current Report |
| May 21, 2025 | 10-K/A | [Amend] Annual report |
| May 20, 2025 | 8-K | Current Report |
| May 16, 2025 | 8-K | Current Report |
| May 9, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-K | Annual Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |